EDIT
Editas Medicine, Inc.
$2.50
+2.46%
$244.8M
No data for this timeframe.
Vol
Market Cap$244.8M
Cap SizeMicro Cap
Analyst ConsensusBuy (68%)
Inst. Holders50 funds
Inst. Value$90.5M
Inst. Activity14 buys / 5 sells
Insider Activity0B / 6S
Insider Net $-$58.1K
SEC Reports10
Press Releases4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001650664·Prev Close $2.44
Recent Activity
Jun 12, 2026
short_volume
Short Volume: EDIT — 71.3% short (0.6M / 0.8M)
Short: 592,280 | Exempt: 2,325 | TRF Vol: 830,159 | Short Ratio: 71.3% | Off-exchange volume (dark p
Jun 11, 2026
SEC
A mixed institutional cluster in Editas Medicine (EDIT) for Q4 2025 shows quant funds D.E. Shaw and Renaissance Technolo
INST-CLUSTER — Impact 5/10
Jun 3, 2026
Insider
Parison Amy sold 464 shares
SVP, Chief Financial Officer @ $2.70 ($1.3K)
Jun 3, 2026
Insider
O'Neill Gilmore Neil sold 15,380 shares
CEO @ $2.70 ($41.5K)
Jun 3, 2026
Insider
Burkly Linda sold 731 shares
EVP, CHIEF SCIENTIFIC OFFICER @ $2.70 ($2.0K)
May 26, 2026
SEC
Editas Medicine is issuing 55,555,556 shares of common stock and accompanying warrants in a $125M underwritten public of
424B5 — Impact 7/10
May 26, 2026
SEC
Editas Medicine priced a dilutive underwritten public offering of 55,555,556 shares of common stock and accompanying war
8-K — Impact 7/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
3,972,160 shares ($9.8M)
Price Targets
$5.78
+131.1% upside
Strong Buy
Current $2.50
Low $1.00
Median $5.00
High $15.00
9 analysts
$1.00
$15.00
Analyst Ratings
4Strong Buy
9Buy
4Hold
2Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 10, 2026 | Jones Trading | UPGRADE | Hold → Buy |
| Mar 9, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.28 ▼ -30.6% | $-0.32 — $-0.24 | 14% YoY | 8 |
| Next Q | $-0.28 ▲ +4.2% | $-0.33 — $-0.24 | 0% YoY | 8 |
| Current FY | $-1.00 ▲ +5.8% | $-1.18 — $-0.61 | 45% YoY | 8 |
| Next FY | $-0.94 ▼ -8.5% | $-1.15 — $-0.46 | 6% YoY | 8 |
Latest Reports
MIXED
INST-CLUSTER
5/10
A mixed institutional cluster in Editas Medicine (EDIT) for Q4 2025 shows quant funds D.E. Shaw and Renaissance Technolo
Jun 11, 2026
BEARISH
424B5
7/10
Editas Medicine is issuing 55,555,556 shares of common stock and accompanying warrants in a $125M underwritten public of
May 26, 2026
BEARISH
Press
8/10
Editas Medicine priced a dilutive underwritten public offering of 55.6M shares and warrants at $2.25 per unit, raising ~
May 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $22.9M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.4M | — |
| RENAISSANCE TECHNOLOGIES LLC | $9.8M | ADD |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7.8M | — |
| STATE STREET CORP | $5.1M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Parison Amy | SELL | $1.3K |
| Jun 3, 2026 | O'Neill Gilmore | SELL | $41.5K |
| Jun 3, 2026 | Burkly Linda | SELL | $2.0K |
| Mar 12, 2026 | Burkly Linda | A | $0.00 |
| Mar 12, 2026 | Parison Amy | A | $0.00 |
50 institutional holders with $90.5M total value (36,666,975 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, RENAISSANCE. Net buying activity: 14 institutions added/increased vs 5 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 9,263,312 | $22.9M | 25.3% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 4,204,369 | $10.4M | 11.5% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 3,972,160 | $9.8M | 10.8% | ADD +30.7% |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3,148,570 | $7.8M | 8.6% | — |
| 5 | STATE STREET CORP | 2,076,122 | $5.1M | 5.7% | — |
| 6 | Nuveen, LLC | 1,977,509 | $4.9M | 5.4% | DOUBLED +120.2% |
| 7 | D. E. Shaw & Co., Inc. | 1,943,893 | $4.8M | 5.3% | DOUBLED +855.1% |
| 8 | TWO SIGMA INVESTMENTS, LP | 1,549,063 | $3.8M | 4.2% | ADD +63.3% |
| 9 | RAYMOND JAMES FINANCIAL INC | 1,293,848 | $3.2M | 3.5% | — |
| 10 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 861,326 | $2.1M | 2.4% | — |
| 11 | MACKENZIE FINANCIAL CORP | 730,054 | $1.8M | 2.0% | — |
| 12 | CITADEL ADVISORS LLC | 662,389 | $1.6M | 1.8% | TRIM -43.3% |
| 13 | VANGUARD FIDUCIARY TRUST CO | 614,036 | $1.5M | 1.7% | — |
| 14 | GOLDMAN SACHS GROUP INC | 558,577 | $1.4M | 1.5% | — |
| 15 | MORGAN STANLEY | 411,192 | $1.0M | 1.1% | TRIM -39.4% |
| 16 | MARSHALL WACE, LLP | 210,308 | $519.5K | 0.6% | — |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 195,100 | $481.9K | 0.5% | — |
| 18 | AMERIPRISE FINANCIAL INC | 155,792 | $384.8K | 0.4% | — |
| 19 | BARCLAYS PLC | 145,602 | $359.6K | 0.4% | — |
| 20 | Mariner, LLC | 145,540 | $359.4K | 0.4% | DOUBLED +252.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 3,039,778 | 3,972,160 | +30.7% | $9.8M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 678,913 | 411,192 | -39.4% | $1.0M | 2026-Q1 |
| Mariner, LLC | DOUBLED | 41,321 | 145,540 | +252.2% | $359.4K | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 95,506 | 141,082 | +47.7% | $348.5K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | ADD | 97,803 | 140,428 | +43.6% | $346.9K | 2026-Q1 |
| Invesco Ltd. | DOUBLED | 54,889 | 136,462 | +148.6% | $337.1K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 193,675 | 134,866 | -30.4% | $333.1K | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 733,483 | 116,995 | -84.0% | $289.0K | 2026-Q1 |
| CWM, LLC | DOUBLED | 44,166 | 105,001 | +137.7% | $259.4K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | ADD | 48,852 | 88,369 | +80.9% | $235.9K | 2026-Q1 |
| STIFEL FINANCIAL CORP | ADD | 44,843 | 80,532 | +79.6% | $198.9K | 2026-Q1 |
| MetLife Investment Management, LLC | DOUBLED | 17,022 | 42,433 | +149.3% | $104.8K | 2026-Q1 |
| CAPTRUST FINANCIAL ADVISORS | ADD | 15,765 | 27,950 | +77.3% | $69.0K | 2026-Q1 |
| HighTower Advisors, LLC | ADD | 11,127 | 19,828 | +78.2% | $49.0K | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | 13,100 | 19,100 | +45.8% | $47.2K | 2026-Q1 |
| COMMONWEALTH EQUITY SERVICES, LLC | TRIM | 20,150 | 14,598 | -27.6% | $36.1K | 2026-Q1 |
| Baird Financial Group, Inc. | TRIM | 20,870 | 10,169 | -51.3% | $25.1K | 2026-Q1 |
| Allworth Financial LP | ADD | 2,381 | 3,488 | +46.5% | $8.6K | 2026-Q1 |
| FEDERATED HERMES, INC. | ADD | 747 | 1,150 | +53.9% | $2.8K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 1,277,400 | 3,039,778 | +138.0% | $6.2M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | DOUBLED | 116,179 | 1,109,590 | +855.1% | $2.3M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 1,087,907 | 678,913 | -37.6% | $1.4M | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 931,910 | 335,479 | -64.0% | $687.7K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 1,024,240 | 193,675 | -81.1% | $397.0K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 128,312 | 162,744 | +26.8% | $333.6K | 2025-Q4 |
3 unique insiders with 9 transactions. Net insider value: -$58.1K ($0.00 bought, $58.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Parison Amy | SVP, Chief Financial Officer | SELL | 464 | $2.70 | $1.3K |
| Jun 3, 2026 | O'Neill Gilmore Neil | CEO | SELL | 15,380 | $2.70 | $41.5K |
| Jun 3, 2026 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | SELL | 731 | $2.70 | $2.0K |
| Mar 12, 2026 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | AWARD | 292,856 | — | — |
| Mar 12, 2026 | Parison Amy | SVP, Chief Financial Officer | AWARD | 292,856 | — | — |
| Mar 12, 2026 | O'Neill Gilmore Neil | CEO | AWARD | 1,015,200 | — | — |
| Mar 3, 2026 | Parison Amy | SVP, Chief Financial Officer | SELL | 474 | $2.02 | $957.48 |
| Mar 3, 2026 | O'Neill Gilmore Neil | CEO | SELL | 5,394 | $2.02 | $10.9K |
| Mar 3, 2026 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | SELL | 749 | $2.02 | $1.5K |
10 SEC filing reports analyzed. Sentiment: 2 bullish, 4 bearish, 1 mixed, 3 neutral. Avg impact: 5.2/10.
MIXED
INST-CLUSTER
5/10
A mixed institutional cluster in Editas Medicine (EDIT) for Q4 2025 shows quant funds D.E. Shaw and
Jun 11, 2026
BEARISH
424B5
7/10
Editas Medicine is issuing 55,555,556 shares of common stock and accompanying warrants in a $125M un
May 26, 2026
BEARISH
8-K
7/10
Editas Medicine priced a dilutive underwritten public offering of 55,555,556 shares of common stock
May 26, 2026
BULLISH
8-K
5/10
Editas Medicine suspended and terminated the prospectus supplement under its at-the-market (ATM) off
May 26, 2026
BEARISH
424B5
7/10
Editas Medicine is conducting a dilutive underwritten public offering of common stock (and/or pre-fu
May 26, 2026
BULLISH
8-K
6/10
Editas Medicine reported new preclinical data for EDIT-401, its lead in vivo gene editing candidate
May 14, 2026
BEARISH
PRESS-RELEASE
6/10
Editas Medicine reported Q1 2026 EPS of -$0.26, slightly worse than the -$0.24 consensus (a miss), w
May 5, 2026
NEUTRAL
8-K
4/10
Editas Medicine reported Q1 2026 results with a net loss of $0.26 per share, narrower than the $0.92
May 5, 2026
NEUTRAL
DEFA14A
2/10
Editas Medicine filed definitive additional proxy materials (DEFA14A) with no substantive new inform
Apr 28, 2026
NEUTRAL
8-K
3/10
Editas Medicine dismissed Ernst & Young as its auditor and appointed PricewaterhouseCoopers (PwC) ef
Apr 7, 2026
BEARISH
8/10
Editas Medicine priced a dilutive underwritten public offering of 55.6M shares and warrants at $2.25
May 26, 2026
BEARISH
6/10
Editas Medicine announced an underwritten public offering of common stock (or pre-funded warrants) a
May 26, 2026
BULLISH
7/10
Editas Medicine presented preclinical data for EDIT-401 at the EAS Congress, showing a single dose a
May 26, 2026
BULLISH
5/10
Editas Medicine presented preclinical data for EDIT-401 at ASGCT, showing ≥90% mean LDL-C reduction
May 14, 2026
Current analyst consensus: Buy (68% buy). Based on 19 analysts: 4 strong buy, 9 buy, 4 hold, 2 sell, 0 strong sell.
Analyst Price Targets
$5.78 mean target
+131.1% upside
Strong Buy (3.00)
$1.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $2.50 |
| Target Low | $1.00 |
| Target Mean | $5.78 |
| Target Median | $5.00 |
| Target High | $15.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.28 | $-0.32 | $-0.24 | 14.4% | -30.6% | 1↑ 1↓ | $0.0B | -23.1% | 8 |
| Next Q 2026-09-30 |
$-0.28 | $-0.33 | $-0.24 | 0.4% | +4.2% | 1↑ 1↓ | $0.0B | -58.7% | 8 |
| Current FY 2026-12-31 |
$-1.00 | $-1.18 | $-0.61 | 44.7% | +5.8% | 4↑ 2↓ | $0.0B | -64.6% | 8 |
| Next FY 2027-12-31 |
$-0.94 | $-1.15 | $-0.46 | 6.0% | -8.5% | 3↑ 1↓ | $0.0B | 2.3% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.275 | |
| 7d ago | $-0.269 | -0.006 |
| 30d ago | $-0.211 | -0.064 |
| 60d ago | $-0.252 | -0.024 |
| 90d ago | $-0.249 | -0.026 |
2 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | Jones Trading | UPGRADE | Hold | Buy |
| Mar 9, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 9 | 4 | 2 | 0 | 68% | |
| May 1, 2026 | 4 | 9 | 5 | 2 | 0 | 65% | |
| Apr 1, 2026 | 4 | 9 | 5 | 2 | 0 | 65% | |
| Mar 1, 2026 | 4 | 8 | 6 | 2 | 0 | 60% | |
| Feb 1, 2026 | 4 | 8 | 6 | 2 | 0 | 60% | |
| Jan 1, 2026 | 4 | 8 | 7 | 2 | 0 | 57% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
$EDIT: Post-Offering Fade Setup I’m Watching Today
▲ 1
💬 1
⚡ 0.5
Jun 12, 2026
short_volume
Short Volume: EDIT — 71.3% short (0.6M / 0.8M)
Short: 592,280 | Exempt: 2,325 | TRF Vol: 830,159 | Short Ratio: 71.3% | Off-exchange volume (dark pool + OTC)
Jun 11, 2026
short_volume
Short Volume: EDIT — 65.1% short (0.6M / 0.9M)
Short: 596,129 | Exempt: 100 | TRF Vol: 915,244 | Short Ratio: 65.1% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: EDIT — 62.7% short (0.5M / 0.8M)
Short: 475,963 | Exempt: 1,814 | TRF Vol: 758,600 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: EDIT — 73.0% short (0.6M / 0.8M)
Short: 619,711 | Exempt: 48,910 | TRF Vol: 849,450 | Short Ratio: 73.0% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: EDIT — 70.2% short (1.0M / 1.4M)
Short: 950,399 | Exempt: 37,284 | TRF Vol: 1,354,180 | Short Ratio: 70.2% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: EDIT — 65.8% short (1.0M / 1.4M)
Short: 952,544 | Exempt: 238 | TRF Vol: 1,446,798 | Short Ratio: 65.8% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: EDIT — 73.9% short (1.2M / 1.6M)
Short: 1,186,652 | Exempt: 62,109 | TRF Vol: 1,606,605 | Short Ratio: 73.9% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: EDIT — 67.3% short (1.6M / 2.3M)
Short: 1,567,034 | Exempt: 76,787 | TRF Vol: 2,330,039 | Short Ratio: 67.3% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: EDIT — 68.1% short (1.0M / 1.5M)
Short: 1,028,626 | Exempt: 0 | TRF Vol: 1,509,577 | Short Ratio: 68.1% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: EDIT — 72.1% short (1.2M / 1.6M)
Short: 1,156,819 | Exempt: 2,077 | TRF Vol: 1,603,775 | Short Ratio: 72.1% | Off-exchange volume (dark pool + OTC)
May 28, 2026
other
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
<p>CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing
May 28, 2026
short_volume
Short Volume: EDIT — 72.2% short (2.0M / 2.8M)
Short: 2,023,321 | Exempt: 1,143 | TRF Vol: 2,804,138 | Short Ratio: 72.2% | Off-exchange volume (dark pool + OTC)
May 26, 2026
offering
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
<p>CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformat
May 26, 2026
offering
Editas Medicine Announces Proposed Public Offering
<p>CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformat
May 26, 2026
fda
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
<p align="center"><em>Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates</em></p>